The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...
— Two T-cell engager antibodies, with clinical data in over 130 patients in oncology, are being repositioned for autoimmune indications — Repeatedly successful senior management team with strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results